Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.43 |
| ▸ | CTSL | P07711 | 4/20 | 0.43 |
| ▸ | CTSS | P25774 | 3/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29123195 | 0.83 | CA1 (0.52) | KMT2AL3MBTL1DRD2 | |
| SCHEMBL14040698 | 0.83 | CTSK (0.57) | CTSKCTSLCTSSKMT2AL3MBTL1 | |
| SCHEMBL29860886 | 0.83 | CA1 (0.52) | KMT2AL3MBTL1DRD2 | |
| SCHEMBL2952653 | 0.83 | CA1 (0.52) | KMT2AL3MBTL1DRD2 | |
| SCHEMBL6225501 | 0.81 | USP30 (0.40) | BACE1KMT2AL3MBTL1 | |
| SCHEMBL3489490 | 0.79 | HSD11B1 (0.50) | CTSKKCNA3 | |
| SCHEMBL14428332 | 0.77 | KMT2A (0.44) | BACE1KMT2AL3MBTL1DRD2 | |
| SCHEMBL6010052 | 0.77 | USP30 (0.54) | BACE1 | |
| SCHEMBL25539152 | 0.77 | FDFT1 (0.46) | — | |
| SCHEMBL31037767 | 0.76 | KMT2A (0.46) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401453-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20040157828-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-08-12 | — | — | US | disclosed |
| EP-1401453-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-31 | — | — | EP | disclosed |
| WO-2002092563-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157828-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CTSK 1/4885CTSL 25/4885CTSS 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.